Wealthy Families Play A Growing Role in European Biotech Financing
Executive Summary
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
You may also be interested in...
Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
Sanofi Pasteur, CureVac Sign Infectious Diseases Vaccine Deal, Win U.S. Government Funding
Private German biotech CureVac wins validation for its RNA-vaccine technology platform with Sanofi Pasteur option deal and enters $33 million research collaboration co-funded by U.S defense department.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.